Cargando…
Bringing pharmacomicrobiomics to the clinic through well‐designed studies
Pharmacomicrobiomic studies investigate drug‐microbiome interactions, such as the effect of microbial variation on drug response and disposition. Studying and understanding the interactions between the gut microbiome and drugs is becoming increasingly relevant to clinical practice due to its potenti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579385/ https://www.ncbi.nlm.nih.gov/pubmed/35899413 http://dx.doi.org/10.1111/cts.13381 |
_version_ | 1784812169647357952 |
---|---|
author | Steiner, Heidi E. Patterson, Hayley K. Giles, Jason B. Karnes, Jason H. |
author_facet | Steiner, Heidi E. Patterson, Hayley K. Giles, Jason B. Karnes, Jason H. |
author_sort | Steiner, Heidi E. |
collection | PubMed |
description | Pharmacomicrobiomic studies investigate drug‐microbiome interactions, such as the effect of microbial variation on drug response and disposition. Studying and understanding the interactions between the gut microbiome and drugs is becoming increasingly relevant to clinical practice due to its potential for avoiding adverse drug reactions or predicting variability in drug response. The highly variable nature of the human microbiome presents significant challenges to assessing microbes’ influence. Studies aiming to explore drug‐microbiome interactions should be well‐designed to account for variation in the microbiome over time and collect data on confounders such as diet, disease, concomitant drugs, and other environmental factors. Here, we assemble a set of important considerations and recommendations for the methodological features required for performing a pharmacomicrobiomic study in humans with a focus on the gut microbiome. Consideration of these factors enable discovery, reproducibility, and more accurate characterization of the relationships between a given drug and the microbiome. Furthermore, appropriate interpretation and dissemination of results from well‐designed studies will push the field closer to clinical relevance and implementation. |
format | Online Article Text |
id | pubmed-9579385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95793852022-10-19 Bringing pharmacomicrobiomics to the clinic through well‐designed studies Steiner, Heidi E. Patterson, Hayley K. Giles, Jason B. Karnes, Jason H. Clin Transl Sci Tutorials Pharmacomicrobiomic studies investigate drug‐microbiome interactions, such as the effect of microbial variation on drug response and disposition. Studying and understanding the interactions between the gut microbiome and drugs is becoming increasingly relevant to clinical practice due to its potential for avoiding adverse drug reactions or predicting variability in drug response. The highly variable nature of the human microbiome presents significant challenges to assessing microbes’ influence. Studies aiming to explore drug‐microbiome interactions should be well‐designed to account for variation in the microbiome over time and collect data on confounders such as diet, disease, concomitant drugs, and other environmental factors. Here, we assemble a set of important considerations and recommendations for the methodological features required for performing a pharmacomicrobiomic study in humans with a focus on the gut microbiome. Consideration of these factors enable discovery, reproducibility, and more accurate characterization of the relationships between a given drug and the microbiome. Furthermore, appropriate interpretation and dissemination of results from well‐designed studies will push the field closer to clinical relevance and implementation. John Wiley and Sons Inc. 2022-08-09 2022-10 /pmc/articles/PMC9579385/ /pubmed/35899413 http://dx.doi.org/10.1111/cts.13381 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Tutorials Steiner, Heidi E. Patterson, Hayley K. Giles, Jason B. Karnes, Jason H. Bringing pharmacomicrobiomics to the clinic through well‐designed studies |
title | Bringing pharmacomicrobiomics to the clinic through well‐designed studies |
title_full | Bringing pharmacomicrobiomics to the clinic through well‐designed studies |
title_fullStr | Bringing pharmacomicrobiomics to the clinic through well‐designed studies |
title_full_unstemmed | Bringing pharmacomicrobiomics to the clinic through well‐designed studies |
title_short | Bringing pharmacomicrobiomics to the clinic through well‐designed studies |
title_sort | bringing pharmacomicrobiomics to the clinic through well‐designed studies |
topic | Tutorials |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579385/ https://www.ncbi.nlm.nih.gov/pubmed/35899413 http://dx.doi.org/10.1111/cts.13381 |
work_keys_str_mv | AT steinerheidie bringingpharmacomicrobiomicstotheclinicthroughwelldesignedstudies AT pattersonhayleyk bringingpharmacomicrobiomicstotheclinicthroughwelldesignedstudies AT gilesjasonb bringingpharmacomicrobiomicstotheclinicthroughwelldesignedstudies AT karnesjasonh bringingpharmacomicrobiomicstotheclinicthroughwelldesignedstudies |